Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report

BACKGROUND: Fingolimod is the first oral agent used for treatment of relapsing-remitting multiple sclerosis. Macular edema, but not retinal hemorrhage, is a well-known adverse effect of fingolimod treatment. To the best of our knowledge, this is the first case report of extensive retinal hemorrhages...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueda, Naoko, Saida, Kyoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4617600/
https://www.ncbi.nlm.nih.gov/pubmed/26481728
http://dx.doi.org/10.1186/s12886-015-0125-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4617600/
https://www.ncbi.nlm.nih.gov/pubmed/26481728
http://dx.doi.org/10.1186/s12886-015-0125-9

Ejemplares similares